Submitted Biologics License Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Submitted biologics license application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Submitted Biologics License Application Today - Breaking & Trending Today

argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline


argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG)
Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedback
Enrolled first 30 patients, necessary for go/no-go decision, in ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP)
Announced interim data from Phase 2 CULMINATE trial of cusatuzumab in development with Janssen
Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted re ....

United States , Kelsey Kirk , Beth Delgiacco , Tim Van Hauwermeiren , Anant Murthy , Bayer Healthcare Pharmaceuticals Inc , Zai Lab Limited , Trial Development , Zai Lab , Drug Administration , Alnylam Pharmaceuticals , Exchange Commission , European Medicines Agency , Devices Agency , Japan Pharmaceuticals , Immunology Innovation Program , Cilag Gmbh International , Submitted Biologics License Application , Greater China , Chief Executive Officer , Immunology Innovation , Medical Devices Agency , General Manager , Market Access , Cusatuzumab Phase , Bayer Healthcare Pharmaceuticals ,